{
    "clinical_study": {
        "@rank": "18408", 
        "arm_group": [
            {
                "arm_group_label": "Group 1, single dose IV of 3BNC117", 
                "arm_group_type": "Experimental", 
                "description": "Group 1 (HIV-uninfected individuals): 1A (1 mg/kg, single dose, IV), 1B (3 mg/kg, single dose, IV), 1C (10 mg/kg, single dose, IV) and expansion subgroup    1D (10 mg/kg, single dose, IV)."
            }, 
            {
                "arm_group_label": "Group 2, single dose IV of 3BNC117", 
                "arm_group_type": "Experimental", 
                "description": "Group 2 (HIV-infected individuals, with HIV-1 RNA levels of 2,000-100,000 copies/ml), off ART): 2A (1 mg/kg, single dose, IV), 2B (3 mg/kg, single dose,      IV), 2C (10 mg/kg, single dose, IV) and expansion subgroup 2D (10 mg/kg, single dose, IV)"
            }, 
            {
                "arm_group_label": "Group 3 single dose IV of 3BNC117", 
                "arm_group_type": "Experimental", 
                "description": "Group 3 (HIV-infected individuals, controllers with HIV-1 RNA levels of < 2,000  copies/ml and off ART): 10 mg/kg, single dose, IV"
            }, 
            {
                "arm_group_label": "Group 4 single dose IV of 3BNC117", 
                "arm_group_type": "Experimental", 
                "description": "Group 4 (HIV-infected individuals, on ART with plasma HIV-1 RNA levels of   21-500 copies/ml): 10 mg/kg, single dose, IV"
            }, 
            {
                "arm_group_label": "Group 5 single dose IV of 3BNC117", 
                "arm_group_type": "Experimental", 
                "description": "Group 5 (HIV-infected individuals, on ART with plasma HIV-1 RNA levels of   1-20 copies/ml): 10 mg/kg, single dose, IV"
            }
        ], 
        "brief_summary": {
            "textblock": "The proposed study is a first-in-man phase I study that aims to evaluate the safety,\n      tolerability and pharmacokinetics of 3BNC117 in HIV-infected and HIV-uninfected subjects,\n      and its antiretroviral activity in HIV-infected subjects."
        }, 
        "brief_title": "A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy", 
            "HIV"
        ], 
        "detailed_description": {
            "textblock": "In preclinical studies carried out in humanized mice and non-human primates, 3BNC117 alone\n      or in combination with other neutralizing antibodies led to protection from HIV-1 or SHIV\n      infection and also to sustained suppression of HIV-1 plasma viremia. The aims of this\n      protocol are to evaluate the safety, tolerability and pharmacokinetics profile of 3BNC117 in\n      both HIV-infected and HIV-uninfected subjects,and its antiretroviral activity in\n      HIV-infected subjects."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Group 1 (HIV-uninfected):\n\n          -  Adult males and females, age 18 to 65\n\n          -  Amenable to HIV risk reduction counseling and agrees to maintaining behavior\n             consistent with low risk of HIV exposure\n\n          -  If sexually active male or female, participating in sexual activity that could lead\n             to pregnancy, agrees to use an effective method of contraception throughout the study\n             period\n\n        Groups 2 - 5  (HIV-infected):\n\n          -  Age 18 to 65\n\n          -  HIV-1 infection confirmed by ELISA and immunoblot\n\n          -  Group 2: Untreated HIV non-controllers (off ART for at least 8 weeks): HIV-1 RNA\n             plasma level of 2,000 -100,000 copies/ml by standard assays, in 2 occasions, at least\n             1 week apart;\n\n          -  Group 3: Untreated HIV controllers (off ART for at least 8 weeks): HIV-1 RNA plasma\n             level of < 2,000 copies/ml by standard assays, in 2 occasions, at least 1 week apart\n\n          -  Group 4: ART-treated with HIV-1 RNA plasma level of 21-500 copies/ml by standard\n             assays in 2 occasions, at least 1 week apart, while on combination antiretroviral\n             therapy\n\n          -  Group 5: ART treated with HIV-1 RNA plasma level of 1-20 copies/ml by a single copy\n             assay in 2 occasions, at least 1 week apart, while on combination antiretroviral\n             therapy\n\n          -  CD4 cell count > 300 cells/\u03bcl and CD4 nadir > 200 cell/\u03bcl\n\n          -  If sexually active male or female, participating in sexual activity that could lead\n             to pregnancy, agrees to use an effective method of contraception throughout the study\n             period.\n\n        Exclusion Criteria:\n\n        Group 1 (HIV-uninfected):\n\n          -  Confirmed HIV-1 or HIV-2 infection\n\n          -  History of immunodeficiency or autoimmune disease; use of systemic corticosteroids,\n             immunosuppressive anti-cancer, or other medications considered significant by the\n             trial physician within the last 6 months\n\n          -  Any clinically significant acute or chronic medical condition that in the opinion of\n             the investigator would preclude participation\n\n          -  Within the 12 months prior to enrollment, the volunteer has a history of sexually\n             transmitted infection\n\n          -  Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies)\n\n          -  Laboratory abnormalities in the parameters listed below:\n\n               -  Absolute neutrophil count equal to or less than 2,000 /mcL\n\n               -  Hemoglobin equal to or less than 12 gm/dL if female and 13.5 gm/dL if male\n\n               -  Platelet count equal to or less than 140,000 /mcL\n\n               -  ALT equal to or higher than 1.25 x ULN\n\n               -  AST equal to or higher than 1.25 x ULN\n\n               -  Total bilirubin equal to or higher than 1.1 ULN\n\n               -  Creatinine equal to or higher than 1.1 x ULN\n\n               -  Coagulation parameters (PT, PTT, INR) equal to or higher than 1.1 x ULN\n\n          -  Pregnancy or lactation\n\n          -  Any vaccination within 14 days prior to 3BNC117 administration\n\n          -  Receipt of any experimental HIV vaccine in the past or monoclonal antibody therapy of\n             any kind in the past\n\n          -  Participation in another clinical study of an investigational product currently or\n             within past 12 weeks, or expected participation during this study\n\n        Groups 2 - 5 (HIV-infected):\n\n          -  Have a history of AIDS-defining illness\n\n          -  History of systemic corticosteroids, immunosuppressive anti-cancer, or other\n             medications considered significant by the trial physician within the last 6 months\n\n          -  Any clinically significant acute or chronic medical condition, other than HIV\n             infection, that in the opinion of the investigator would preclude participation\n\n          -  Hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies)\n\n          -  Laboratory abnormalities in the parameters listed below:\n\n               -  Absolute neutrophil count equal to or less than 1,300 / mcL\n\n               -  Hemoglobin equal to or less than 10 gm/dL\n\n               -  Platelet count equal to or less than 125,000\n\n               -  ALT equal to or higher than 2.0 x ULN\n\n               -  AST equal to or higher than 2.0 x ULN\n\n               -  Total bilirubin equal to or higher than 1.1 ULN\n\n               -  Creatinine equal to or higher than 1.1 x ULN\n\n          -  Coagulation parameters equal to or higher than 1.1 x ULN\n\n          -  Pregnancy or lactation\n\n          -  Any vaccination within 14 days prior to 3BNC117 administration\n\n          -  Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in\n             the past\n\n          -  Participation in another clinical study of an investigational product currently or\n             within past 12 weeks, or expected participation during this study\n\n          -  Current ART regimen includes either maraviroc or enfuvirtide"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "61", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018510", 
            "org_study_id": "MCA-0835"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1, single dose IV of 3BNC117", 
                    "Group 2, single dose IV of 3BNC117"
                ], 
                "description": "1 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_name": "1 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 1, single dose IV of 3BNC117", 
                    "Group 2, single dose IV of 3BNC117"
                ], 
                "description": "3 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_name": "3 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Group 1, single dose IV of 3BNC117", 
                    "Group 2, single dose IV of 3BNC117", 
                    "Group 3 single dose IV of 3BNC117", 
                    "Group 4 single dose IV of 3BNC117", 
                    "Group 5 single dose IV of 3BNC117"
                ], 
                "description": "10 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_name": "10 mg/kg, single dose IV administration of 3BNC117", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Healthy Volunteers", 
            "HIV"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "contact": {
                "email": "rucares@rockefeller.edu", 
                "last_name": "Lauren Corregano", 
                "phone": "800-782-2737"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "The Rockefeller University"
            }, 
            "investigator": {
                "last_name": "Marina Caskey, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety and tolerability profile of a single intravenous infusion of 3BNC117 at 3 increasing dose levels in HIV-infected and HIV-uninfected individuals.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018510"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To determine the pharmacokinetic profile of a single intravenous administration of 3BNC117 in HIV-uninfected and HIV-infected subjects.", 
            "measure": "Pharmacokinetic profile", 
            "safety_issue": "No", 
            "time_frame": "24 hours post infusion"
        }, 
        "source": "Rockefeller University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rockefeller University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}